Replies to post #22352 on Biotech Values

[DewDiligence]

I was able to catch the NPSP webcast from JPM. It’s on my list for more DD as time permits.

Are you concerned about the manifold competitors in the PTH space? There’s EMIS’ oral program, NSTK’s intranasal program, the new LLY-ALKS partnership, and of course, Forteo.

[nymup]

UnderValued Bio's...LEXG

LEXG get's my vote as most undervalued biotech. As you may know, they are in the business of finding new/novel drug targets. They have an on-going program, Genome5000, to identify the function of 5000 genes. So far, their research has led to over 70 drug development programs and multiple partnerships. Revenues for the year are in the $70M range with ~15% growth per year. They, and their partners, have yet to put a drug into clinical trials. When that happens, milestones, revenues, and PPS should explode.

The price is currently near 4 year lows. This past year they canceled the NDA for their first drug and the share price took a beating. IMO, it's worth a look.